Vivos Therapeutics Q4 2023 GAAP EPS $(3.05) Misses $(1.91) Estimate, Sales $3.248M Miss $3.406M Estimate
Portfolio Pulse from Benzinga Newsdesk
Vivos Therapeutics reported Q4 2023 earnings with a GAAP EPS of $(3.05), missing the $(1.91) estimate, and sales of $3.248M, missing the $3.406M estimate. This represents a 17.77% decrease in sales compared to the same period last year.

March 28, 2024 | 8:42 pm
News sentiment analysis
Sort by:
Descending
NEGATIVE IMPACT
Vivos Therapeutics reported a significant miss in both EPS and sales for Q4 2023, with a 17.77% YOY decrease in sales.
Missing both EPS and sales estimates significantly, especially with a larger than expected loss per share, typically leads to negative investor sentiment and could result in a short-term decrease in stock price. The year-over-year decrease in sales further compounds concerns about the company's growth trajectory.
CONFIDENCE 90
IMPORTANCE 90
RELEVANCE 100